In line with the Hsp90 connection to K-Ras, a synergistic activity of Hsp90 inhibitors with MAPK-pathway inhibitors in KRAS mutant pancreatic ductal adenocarcinoma was reported [54]. This evidence concerns the gene HSP90AA1 and pancreatic ductal adenocarcinoma.